Caplin Point Laboratories Ltd.

View in App
1316.95 +19.90 ▲1.5%

16 April 2024, 04:01:00 PM
Volume: 3,726

Company Profile

View details >>
Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.caplinpoint.net
Market Cap 10,000.01 Cr.
Enterprise Value(EV) 9,436.00 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 57.62 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 22.85 Trailing Twelve Months Ending 2023-12
Industry PE 41.15 Trailing Twelve Months Ending 2023-12
Book Value / Share 288.83 Trailing Twelve Months Ending 2023-12
Price to Book Value 4.56 Calculated using Price: 1,316.80
Dividend Yield 0.34 Period Ending 2023-03
No. of Shares Subscribed 7.59 Cr. 75,941,746 Shares
FaceValue 2
About Caplin Point Laboratories Ltd.
Caplin Point is the mid-sized company in India's pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.

Caplin Point Laboratories Ltd. Delivery

View details >>
Delivered Qty
Traded Qty

Caplin Point Laboratories Ltd. Performance

View details >>
1 Day
+1.53%
1 Week
+1.52%
1 Month
+2.63%
3 Month
-9.23%
6 Month
+19.00%
1 Year
+109.44%
2 Year
+71.36%
5 Year
+236.00%
10 Year
+3834.72%

Caplin Point Laboratories Ltd. Fundamental Ratios

View details >>
9 years 2015-06 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 55.78 43.13 54.97 49.43 37.14 29.58 25.65 24.77 23.68
Return on Capital Employed (%) 71.11 55.41 69.03 64.08 45.59 33.35 28.82 28.77 26.85
Return on Assets (%) 20.12 18.46 30.54 33.68 28.41 23.02 20.2 19.94 19.29

Caplin Point Laboratories Ltd. Balance Sheet

View details >>
Particulars 10 years 2015-06 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 93 128 225 364 633 948 1,186 1,484 1,880 2,074
Non Curr. Liab. 10 14 20 28 23 25 17 13 2 0
Curr. Liab. 125 125 113 109 86 144 143 208 268 294
Minority Int. 0 0 0 0 0 9 18 26 27 29
Equity & Liab. 229 267 358 500 743 1,126 1,364 1,730 2,178 2,397
Non Curr. Assets 147 149 179 196 249 303 349 432 623 728
Curr. Assets 82 119 179 304 494 823 1,015 1,298 1,554 1,668
Misc. Exp. not W/O
Total Assets 229 267 358 500 743 1,126 1,364 1,730 2,178 2,397

Caplin Point Laboratories Ltd. Profit and Loss

View details >>
Particulars 10 years 2015-06 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 252 239 402 540 649 863 1,061 1,269 1,467 1,630
Other Income 3 4 10 13 19 41 28 39 57 61
Total Income 255 242 412 553 668 905 1,089 1,308 1,523 1,691
Total Expenditure -192 -175 -277 -345 -417 -603 -737 -875 -1,026 -1,100
PBIDT 63 68 135 208 251 301 352 433 497 591
Interest -1 0 -1 -1 -1 0 -2 -1 -1 -1
Depreciation -8 -7 -13 -19 -23 -32 -37 -47 -45 -48
Taxation -12 -14 -25 -44 -50 -54 -62 -77 -74 -101
Exceptional Items
PAT 41 46 96 145 177 215 251 308 377 441
Minority Interest 0 0 0 0 -9 -9 -1 -4
Share Associate 0
Other Related Items
Consolidated Net Profit 41 46 96 145 177 215 242 300 376 438
Adjusted EPS 5 6 13 19 23 28 32 40 50 58

Caplin Point Laboratories Ltd. Cash Flow

View details >>
Particulars 10 years 2014-06 Rs. Cr. 2015-06 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 60 50 42 68 66 83 45 269 337 271
Cash Fr. Inv. -44 -23 -6 -36 -69 -100 -55 -29 -377 -218
Cash Fr. Finan. -6 -9 -14 -7 -12 90 80 -24 -41 -28
Net Change 10 19 23 25 -14 73 70 215 -81 26
Cash & Cash Eqvt 27 45 68 91 77 151 221 436 151 178

Caplin Point Laboratories Ltd. Shareholding Pattern

View details >>
9 Qtrs 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 68.91 68.89 68.88 68.88 68.80 70.66 70.63 70.63 70.62
Public 31.09 31.11 31.12 31.12 31.20 29.34 29.37 29.37 29.38
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
No. of Shareholders (in Lacs)

Caplin Point Laboratories Ltd. Announcements

View details >>
Wed, 17 Apr 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of loss of share certificates are attached herewith
Tue, 16 Apr 2024
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find the attached Press Release on USFDA approval for Ofloxacin Ophthalmic Solution ANDA.
Sat, 13 Apr 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of loss of share certificate is attached herewith

Caplin Point Laboratories Ltd. Technical Scans

View details >>
Tue, 16 Apr 2024
Opening at Low Opening at Low
Closing Above Previous High Closing Above Previous High
Opening at Low for 2 Days Opening at Low for 2 Days
High Decrease in 3 Months High Decrease in 3 Months
High Increase in 6 Months High Increase in 6 Months

Caplin Point Laboratories Ltd. Related Stocks

View details >>
  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 368,765.79 1,536.95 -0.3%
Cipla Ltd. 111,101.58 1,384.30 +0.2%
Dr. Reddy's Laboratories Ltd. 100,958.41 6,038.00 +0.5%
Divi's Laboratories Ltd. 99,939.63 3,755.15 +1.1%
Zydus Lifesciences Ltd. 95,104.21 937.80 +0.3%
Mankind Pharma Ltd. 91,420.29 2,295.00 +1.3%
Apollo Hospitals Enterprise Ltd. 91,073.20 6,327.80 +0.4%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 41.41 1,536.95 -0.3%
Cipla Ltd. Consolidated 2023-12 29.96 1,384.30 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 19.31 6,038.00 +0.5%
Divi's Laboratories Ltd. Consolidated 2023-12 72.26 3,755.15 +1.1%
Zydus Lifesciences Ltd. Consolidated 2023-12 31.98 937.80 +0.3%
Mankind Pharma Ltd. Consolidated 2023-12 52.93 2,295.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 115.38 6,327.80 +0.4%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.91 1,536.95 -0.3%
Cipla Ltd. Consolidated 2023-12 4.29 1,384.30 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.76 6,038.00 +0.5%
Divi's Laboratories Ltd. Consolidated 2023-12 7.67 3,755.15 +1.1%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.05 937.80 +0.3%
Mankind Pharma Ltd. Consolidated 2023-12 10.29 2,295.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 13.48 6,327.80 +0.4%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,536.95 -0.3%
Cipla Ltd. Consolidated 2023-03 0.02 1,384.30 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,038.00 +0.5%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,755.15 +1.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 937.80 +0.3%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,295.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,327.80 +0.4%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,536.95 -0.3%
Cipla Ltd. Consolidated 2023-03 12.85 1,384.30 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,038.00 +0.5%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,755.15 +1.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 937.80 +0.3%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,295.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,327.80 +0.4%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,536.95 -0.3%
Cipla Ltd. Consolidated 2023-03 12.85 1,384.30 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,038.00 +0.5%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,755.15 +1.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 937.80 +0.3%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,295.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,327.80 +0.4%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,536.95 -0.3%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,384.30 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,038.00 +0.5%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,755.15 +1.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 937.80 +0.3%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,295.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,327.80 +0.4%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,536.95 -0.3%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,384.30 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,038.00 +0.5%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,755.15 +1.1%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 937.80 +0.3%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,295.00 +1.3%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,327.80 +0.4%

Caplin Point Laboratories Ltd. FAQ's

What is Caplin Point Lab share price?
Can I buy Caplin Point Lab shares now?
What is the Dividend Yield of Caplin Point Lab?
What is the Market Cap of Caplin Point Lab?
What are the key metrics to analyse Caplin Point Lab?
What is the 52 Week High and Low of Caplin Point Lab?
What is the trend of Caplin Point Lab share price?